DR PETER VAN ESS

Translational Medicine (Clinical Pharmacology and Clinical Development)

Pete Van Ess, PharmD PhD, has over 20 years of experience spanning the areas of non-clinical development through late stage clinical development. He has played key roles in progressing new chemical entities from IND enabling studies to FIH testing and clinical proof of concept. Additionally, Pete has experience in Generic Drug Development and late stage Clinical Development as a major contributor to Regulatory approvals in the US and EU (NDA, sNDA, ANDA and MAA).


Previously serving roles in Biotech, mid and large companies, including Chief Development Officer and VP of Translational Medicine (Proximagen LLC), Head of Translational Medicine or Clinical Pharmacology (Upsher Smith Pharmaceuticals, Great Lakes Drug Development and deCODE genetics) and as a project Clinical Pharmacologist (Pfizer/Pharmacia), leading Translational Medicine strategy and tactical “hands on” design, management and/or execution of non-clinical and clinical studies, analytics including modeling and simulation (NCA and population PKPD, PBPK, allometric scaling, etc.), bioanalysis, biomarker application and leveraging novel early and late stage clinical designs.


Pete has been a major contributor to business initiatives including co-development, in-licensing and out-licensing of assets and entrepreneurial company start up or spin-out. He completed his PhD training in Clinical Pharmacology and Experimental Therapeutics at the University of Kentucky-Lexington and his Pharmacy training at the University of Wisconsin-Madison.

 

©2019 DRUG DISCOVERY AND DEVELOPMENT CONSULTANTS LTD. TRADING AS 3D CONSULTANTS. REGISTERED IN ENGLAND AND WALES, COMPANY NUMBER 11438683